 |
 |
I can't figure out why it won't work when the original one works! Anyway, here is the article: 1: Neurology. 2003 Aug 12;61(3):297-303. Related Articles, Links Comment in: Neurology. 2003 Aug 12;61(3):286-7. Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD. Hauser RA, Hubble JP, Truong DD; Istradefylline US-001 Study Group. Department of Neurology, University of South Florida, and Tampa General Healthcare, 33606, USA. [log in to unmask] OBJECTIVE: To evaluate the safety and efficacy of the adenosine A(2A) receptor antagonist istradefylline (KW-6002) in patients with levodopa-treated Parkinson's disease (PD) with both motor fluctuations and peak-dose dyskinesias. METHODS: This was a 12-week, double-blind, randomized, placebo-controlled, exploratory study in which PD subjects with both motor fluctuations and peak-dose dyskinesias were randomized to treatment with placebo (n = 29), istradefylline up to 20 mg/day (n = 26), or istradefylline up to 40 mg/day (n = 28). There was no prespecified primary outcome measure, and 19 outcome variables were analyzed. RESULTS: As assessed by home diaries, subjects assigned to istradefylline experienced a mean (+/- SE) reduction in the proportion of awake time spent in the "off" state of 7.1 +/- 2.0% compared with an increase of 2.2 +/- 2.7% in the placebo group (p = 0.008). There was a decrease in "off" time of 1.2 +/- 0.3 hours in the istradefylline group compared with an increase of 0.5 +/- 0.5 hour in the placebo group (p = 0.004). Dyskinesia severity was unchanged, but "on" time with dyskinesia increased in the istradefylline group compared with the placebo group (percent, p = 0.002; hours, p = 0.001). No differences were observed in change in Unified Parkinson's Disease Rating Scale scores or Clinical Global Impression of Change. Twenty-four percent of placebo-assigned subjects and 20% of istradefylline-assigned subjects withdrew from the study. Both dose regimens of istradefylline were generally well tolerated, and nausea was the most common adverse event. CONCLUSION: Istradefylline was generally well tolerated and reduced "off" time as assessed by home diaries. Severity of dyskinesia was unchanged, but "on" time with dyskinesia increased. Publication Types: Clinical Trial Multicenter Study Randomized Controlled Trial PMID: 12913187 [PubMed - indexed for MEDLINE] -----Original Message----- From: Parkinson's Information Exchange Network [mailto:[log in to unmask]] On Behalf Of Brightline Sent: Thursday, October 14, 2004 5:23 AM To: [log in to unmask] Subject: Re: FW:Curcumin/ CDP choline = istradefylline Sorry! No luck again Raj ******** ----- Original Message ----- From: Wendy Siegel <[log in to unmask]> To: <[log in to unmask]> Sent: Wednesday, October 13, 2004 11:42 PM Subject: Re: FW:Curcumin/ CDP choline = istradefylline > The link got broken when I forwarded the message. Try this one: > http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dop > t=Abstract&list_uids=12913187 > > Wendy > ---------------------------------------------------------------------- To sign-off Parkinsn send a message to: mailto:[log in to unmask] In the body of the message put: signoff parkinsn